Cure My Disease

Don't miss your cure!

 Log in / Sign up

New drug cocktail shows promise in halting lung cancer after chemo

NCT ID NCT06606847

Ongoing Disease control Sponsor: AstraZeneca Source: ClinicalTrials.gov ↗

First seen Nov 01, 2025 · Last updated May 14, 2026 · Updated 33 times

Summary

This study tests whether combining two immunotherapy drugs, durvalumab and oleclumab, can help people with advanced lung cancer that hasn't spread after initial chemoradiation. About 30 adults with stage III non-small cell lung cancer will receive the drug combo. The main goal is to see how many patients remain cancer-free for at least 12 months.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for NON SMALL CELL LUNG CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • Research Site

    Kazan', 420029, Russia

  • Research Site

    Moscow, 111123, Russia

  • Research Site

    Moscow, 115478, Russia

  • Research Site

    Moscow, 143423, Russia

  • Research Site

    Nizhny Novgorod, 603126, Russia

  • Research Site

    Novosibirsk, 630108, Russia

  • Research Site

    Obninsk, 249031, Russia

  • Research Site

    Saint Petersburg, 197022, Russia

  • Research Site

    Saint Petersburg, 197758, Russia

  • Research Site

    Ufa, 450054, Russia

  • Research Site

    Yekaterinburg, 620905, Russia

Conditions

Explore the condition pages connected to this study.

NON SMALL CELL LUNG CANCER NON-SMALL CELL LUNG CANCER